NTP study supports safety of chromium pico

US supplements giant Nutrition 21 says study results released by the National Toxicology Program support the safety of short-term and long-term use of chromium picolinate. Multiple safety trial were performed in animals, including a two-year study using daily doses of chromium picolinate equivalent to 50,000 times the common human dose found in supplements.

Michael Zeher, chief executive of Nutrition 21, said: "over the years, Chromax chromium picolinate has proven to be an efficacious compound in assisting consumers to safely and proactively attain, and maintain, healthy blood glucose levels, carbohydrate metabolism and body composition."

"The results from the NTP studies are very significant in that chromium picolinate did not cause any dose-related safety issues, even when used at extremely high doses taken over prolonged periods of time," said toxicology expert Ron Slesinski, past president of the regulatory and safety specialty section of the Society of Toxicology. "I believe that the safety profile of chromium picolinate is firmly established by the results of these independent studies," he added.